Ahead of R&D day, Moderna unveils two rare disease deals

Moderna’s deals with Vertex and Chiesi Group highlight the company’s ongoing bid to deploy its technology across a wide range of therapeutic areas, even as infectious diseases get top billing.

On Wednesday, Moderna Inc. (NASDAQ:MRNA) announced it established a second cystic fibrosis (CF) deal with  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), this time focused on editing the CFTR gene, and initiated a collaboration with Chiesi Farmaceutici S.p.A. to develop mRNA therapies for pulmonary arterial hypertension (PAH)...